{"transactions":[{"id":740038,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-06-12T20:16:06.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":9250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":9250,"derivative":{"exercise_price":13.22,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":9250},"source":{"system":"sec-edgar","filing":"0001887762-26-000002","document":"form4-06122026_080602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000188776226000002/form4-06122026_080602.xml","form_type":"4"}},{"id":1115087,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-06-11T21:48:27.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares of Common Stock subject to the option shall vest on a monthly basis following the grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the Reporting Person remaining in service as a director through the applicable vesting date."}],"balance_after":13000,"derivative":{"exercise_price":12.47,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001415889-25-016730","document":"form4-06112025_090624.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925016730/form4-06112025_090624.xml","form_type":"4"}},{"id":1944138,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-03-20T20:05:17.000Z","date":"2023-03-16","kind":"purchase","planned":false,"acquired":true,"shares":11000,"price":2.247,"value":24717.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.21 to $2.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0000899243-23-009095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924323009095/doc4.xml","form_type":"4"}},{"id":1986144,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-28T23:56:45.000Z","date":"2023-02-25","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023."}],"balance_after":135000,"derivative":{"exercise_price":1.78,"expiration_date":"2033-02-24","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0000899243-23-006468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924323006468/doc4.xml","form_type":"4"}},{"id":2359493,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T21:05:43.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022."}],"balance_after":75000,"derivative":{"exercise_price":2.24,"expiration_date":"2032-02-27","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-008580","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924322008580/doc4.xml","form_type":"4"}},{"id":2544282,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":38771,"kind":"person","name":"Bachleda Mark","position":1,"cik":"0001887762","reported_name":"Bachleda Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-13T00:23:52.000Z","date":"2021-10-08","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% on October 8, 2022, and in thirty-six (36) substantially equal monthly installments over a three year period thereafter."}],"balance_after":200000,"derivative":{"exercise_price":7.84,"expiration_date":"2031-10-07","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-21-039959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563577/000089924321039959/doc4.xml","form_type":"4"}}]}